Business Context and Reporting Period
Company: MaxCyte, Inc. (MXCT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: MaxCyte is a global life sciences company focused on cell engineering technologies (Flow Electroporation) for the discovery, development, and commercialization of cell therapies. The company generates revenue through the sale and lease of instruments, consumables, and strategic platform license (SPL) agreements.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $10,429 | $9,043 | $21,770 | $17,619 |
| Gross Profit | $8,941 | $7,667 | $18,879 | $15,243 |
| Gross Margin | 86% | 85% | 87% | 87% |
| Operating Loss | $(11,968) | $(13,073) | $(24,243) | $(26,251) |
| Net Loss | $(9,375) | $(10,512) | $(18,901) | $(21,394) |
| Net Loss Per Share (Basic/Diluted) | $(0.09) | $(0.10) | $(0.18) | $(0.21) |
| Cash and Cash Equivalents (End of Period) | $37,513 | $54,557 | $37,513 | $54,557 |
| Total Investments (Short & Long Term) | $162,298 | $164,720 | $162,298 | $164,720 |
| Accumulated Deficit | $(194,699) | $(159,269) | $(194,699) | $(159,269) |
Liquidity: As of June 30, 2024, the company held $37.5 million in cash and cash equivalents and $162.3 million in investments. The company reported no debt obligations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15% in Q2 2024 and 24% for the six months ended June 30, 2024, compared to the prior year periods. This growth was primarily driven by a significant increase in program-related revenue (milestones) rather than core product sales.
- Core Revenue Decline: Core revenue (instruments, disposables, leases) decreased 9% in Q2 and 2% for the six months. Instrument sales and lease revenue declined, partially offset by growth in disposable sales.
- Program-Related Revenue: Program-related revenue surged 279% in Q2 and 286% for the six months, reflecting the achievement of clinical and regulatory milestones under SPL agreements.
- Operating Expenses: Total operating expenses remained relatively flat in Q2 but increased slightly for the six-month period. Sales and marketing expenses rose 10% year-over-year for the six months due to increased headcount and compensation.
- Cash Flow: Net cash used in operating activities was $15.4 million for the six months ended June 30, 2024, compared to $14.4 million in the prior year period. The company generated $5.0 million from investing activities, primarily from the net maturity of investments.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses as it invests in commercial sales, manufacturing scale-up, and R&D. The company believes its current cash, cash equivalents, and investments are sufficient to fund operations for at least the next 12 months.
- Strategic Focus: The company continues to sign new Strategic Platform License (SPL) agreements. Five new partners were signed in the first half of 2024 (Lion TCR, Imugene, Wugen, Be Biopharma, and Legend Biotech).
- Risks:
- Revenue Variability: Program-related revenue is highly variable and dependent on the timing of partner milestones.
- Customer Concentration: Two customers represented 32% of revenue for the six months ended June 30, 2024.
- Supplier Concentration: 27% of inventory additions for the six months came from a single supplier.
- Capital Requirements: Future funding needs depend on market acceptance and the progress of partners' pipelines. Additional equity or debt financing may be required, potentially causing dilution.
Key Facts for Investor Verification
- Milestone Dependency: Verify the sustainability of revenue growth given that the increase was driven almost entirely by non-recurring milestone payments rather than recurring core product sales.
- Cash Burn Rate: Monitor the net cash used in operating activities ($15.4M for six months) against the total cash and investment balance (~$200M) to assess runway.
- Core Revenue Trends: Investigate the decline in core instrument and lease revenue to understand if it indicates market saturation or competitive pressure.
- Concentration Risk: Assess the impact of the top two customers (32% of revenue) and the primary inventory supplier (27% of additions) on operational stability.
- Stock-Based Compensation: Note that stock-based compensation was $6.6 million for the six months ended June 30, 2024, representing a significant non-cash expense impacting net loss.